XORTX Therapeutic Inc.

[Available On-Demand]

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing therapies to treat kidney disease. The Company has three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus/COVID-19 infection and XRx-221, for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism. We develop medications to improve the quality of life and future of patients with kidney disease. 

Ticker:
XRX and XRTXF
Exchange:
CSE and OTCQB
Company Type:
Company Website:
Not Provided
Company HQ State:
Not Provided
Company HQ Country:
Canada
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Not Provided
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2